SEHK:1875Biotechs
BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses
BioDlink International has been trading like a recovery story, with the stock up about 17% over the past month. However, H1 2026 results underline that this is still a loss making biotech with a valuation built on hope rather than profit. The headline this half is the profit squeeze. Revenue came in at ¥246.011 million, while net income excluding extra items showed a loss of ¥58.517 million and basic earnings per share were also in the red. The share price reaction now rests on how long...